Human Papilloma Virus as a Biomarker for Personalized Head and Neck Cancer Radiotherapy.
A dramatic increase in the incidence of HPV-related oropharyngeal cancer has been reported in some parts of the western world over the past 30 years. They constitute a clinically distinct subgroup of cancers in terms of molecular biology, patient characteristics, and treatment outcome. This chapter describes the molecular characteristics, epidemiology, and demographics of the HPV-related head and neck cancers and discuss available methods to detect HPV-related tumours. The impact of HPV-related biomarkers in clinical studies on radiotherapy only, altered fractionation, modulation of hypoxia, and concurrent chemo- or bio-radiotherapy are reviewed as well as the perspectives of de-escalation and immune-modulation are discussed.
Department of Oncology, Odense University Hospital, Odense, Denmark. jesper.grau.eriksen@rsyd.dk.
Jesper Grau
JG
Eriksen
Department of Oncology, Department of Clinical Experimental Oncology, Aarhus University Hospital, 8000, Aarhus C, Denmark.
Pernille
P
Lassen
D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy* / Q000821:virology; D059248:Chemoradiotherapy; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000532:radiotherapy* / Q000821:virology; D054884:Host-Pathogen Interactions / Q000187:drug effects / Q000528:radiation effects; D006801:Humans; D009856:Oncogene Proteins, Viral / Q000032:analysis; D027383:Papillomaviridae / Q000187:drug effects / Q000502:physiology / Q000528:radiation effects*; D030361:Papillomavirus Infections / Q000188:drug therapy / Q000532:radiotherapy* / Q000821:virology; D057285:Precision Medicine / Q000379:methods*; D011379:Prognosis
D009856:Oncogene Proteins, Viral
De-intensification; HPV; Head and neck cancer; Hypoxia; P16; Radiotherapy